Hong Sang

Array ( [id] => 16190814 [patent_doc_number] => 20200231663 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-23 [patent_title] => Compositions and Methods for Treating Cancer with Anti-Mesothelin Immunotherapy [patent_app_type] => utility [patent_app_number] => 16/780325 [patent_app_country] => US [patent_app_date] => 2020-02-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27151 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16780325 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19060181 [patent_doc_number] => 11939390 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-26 [patent_title] => Methods of treating multiple myeloma [patent_app_type] => utility [patent_app_number] => 16/775025 [patent_app_country] => US [patent_app_date] => 2020-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 36682 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 188 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16775025 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16452620 [patent_doc_number] => 20200362046 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-19 [patent_title] => DE NOVO BINDING DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/751730 [patent_app_country] => US [patent_app_date] => 2020-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 66527 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16751730 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17428394 [patent_doc_number] => 20220056102 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-24 [patent_title] => MULTI-FUNCTIONAL FUSION PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/421053 [patent_app_country] => US [patent_app_date] => 2020-01-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23421 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17421053 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15797283 [patent_doc_number] => 20200121784 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-23 [patent_title] => Tissue Targeted Antigenic Activation of the Immune Response to Treat Cancers [patent_app_type] => utility [patent_app_number] => 16/732557 [patent_app_country] => US [patent_app_date] => 2020-01-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49862 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16732557 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16090495 [patent_doc_number] => 20200199234 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-25 [patent_title] => TUMOR-TARGETED AGONISTIC CD28 ANTIGEN BINDING MOLECULES [patent_app_type] => utility [patent_app_number] => 16/721272 [patent_app_country] => US [patent_app_date] => 2019-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 108110 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -62 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16721272 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17648552 [patent_doc_number] => 11351255 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-06-07 [patent_title] => Treatment of cancer with therapeutic monoclonal antibody specific for a tumor associated antigen and an immune adjuvant [patent_app_type] => utility [patent_app_number] => 16/702323 [patent_app_country] => US [patent_app_date] => 2019-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 12846 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 186 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16702323 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15681335 [patent_doc_number] => 20200095331 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-26 [patent_title] => PHOTOSENSITIZING ANTIBODY-FLUOROPHORE CONJUGATES [patent_app_type] => utility [patent_app_number] => 16/695674 [patent_app_country] => US [patent_app_date] => 2019-11-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18475 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16695674 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18701373 [patent_doc_number] => 11787872 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-17 [patent_title] => Methods and compositions related to antibody fragments that bind to tumor-associated glycoprotein 72 (TAG-72) [patent_app_type] => utility [patent_app_number] => 16/694052 [patent_app_country] => US [patent_app_date] => 2019-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 61 [patent_no_of_words] => 31523 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 196 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16694052 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18005405 [patent_doc_number] => 20220364171 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-17 [patent_title] => PREDICTING A TREATMENT RESPONSE IN INFLAMMATORY BOWEL DISEASE [patent_app_type] => utility [patent_app_number] => 17/296415 [patent_app_country] => US [patent_app_date] => 2019-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 59239 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17296415 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15646841 [patent_doc_number] => 20200085950 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-19 [patent_title] => PHOTOSENSITIZING ANTIBODY-FLUOROPHORE CONJUGATES [patent_app_type] => utility [patent_app_number] => 16/694761 [patent_app_country] => US [patent_app_date] => 2019-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27660 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16694761 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15963169 [patent_doc_number] => 20200165336 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-28 [patent_title] => MCAM ANTAGONISTS AND METHODS OF TREATMENT [patent_app_type] => utility [patent_app_number] => 16/691525 [patent_app_country] => US [patent_app_date] => 2019-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22632 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16691525 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19667567 [patent_doc_number] => 12180295 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-31 [patent_title] => Humanized anti-SIRPa antibodies [patent_app_type] => utility [patent_app_number] => 17/292182 [patent_app_country] => US [patent_app_date] => 2019-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 32438 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17292182 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15646801 [patent_doc_number] => 20200085930 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-19 [patent_title] => PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST NON-SMALL CELL LUNG CANCER AND OTHER CANCERS [patent_app_type] => utility [patent_app_number] => 16/681472 [patent_app_country] => US [patent_app_date] => 2019-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26858 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 105 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16681472 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16175584 [patent_doc_number] => 20200222552 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-16 [patent_title] => PHARMACEUTICAL FORMULATIONS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/680930 [patent_app_country] => US [patent_app_date] => 2019-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18080 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16680930 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17733350 [patent_doc_number] => 20220218809 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-14 [patent_title] => IDO ACTIVITY AS A MARKER OF TUMOR IMMUNE ESCAPE AND IDO INHIBITORS AS A MEANS OF ENHANCING T CELLS RESPONSE TO ANTIGEN SPECIFIC VACCINE [patent_app_type] => utility [patent_app_number] => 17/291159 [patent_app_country] => US [patent_app_date] => 2019-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10396 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17291159 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17443777 [patent_doc_number] => 20220064282 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-03 [patent_title] => ANTIBODY BINDING TO HUMAN IL-1 BETA, PREPARATION METHOD THEREFOR AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/292384 [patent_app_country] => US [patent_app_date] => 2019-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12201 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17292384 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15493289 [patent_doc_number] => 20200046833 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-13 [patent_title] => AGONIST ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/669061 [patent_app_country] => US [patent_app_date] => 2019-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 72689 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16669061 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16367835 [patent_doc_number] => 10799570 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-10-13 [patent_title] => Peptides and combination of peptides as targets or active ingredients for use in immunotherapy against AML and other cancers [patent_app_type] => utility [patent_app_number] => 16/669192 [patent_app_country] => US [patent_app_date] => 2019-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 9 [patent_no_of_words] => 33206 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16669192 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15493261 [patent_doc_number] => 20200046819 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-13 [patent_title] => NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AS TARGETS OR ACTIVE INGREDIENTS FOR USE IN IMMUNOTHERAPY AGAINST AML AND OTHER CANCERS [patent_app_type] => utility [patent_app_number] => 16/668666 [patent_app_country] => US [patent_app_date] => 2019-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33553 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 164 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16668666 [rel_patent_id] =>[rel_patent_doc_number] =>)